Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Scheipner, L; Tappero, S; Piccinelli, ML; Barletta, F; Garcia, CC; Incesu, RB; Morra, S; Baudo, A; Tian, Z; Saad, F; Shariat, SF; Terrone, C; De, Cobelli, O; Briganti, A; Chun, FKH; Tilki, D; Longo, N; Carmignani, L; Pichler, M; Hutterer, G; Ahyai, S; Karakiewicz, PI.
Regional differences in clear cell metastatic renal cell carcinoma patients across the USA.
World J Urol. 2023; 41(11): 2991-3000.
Doi: 10.1007/s00345-023-04589-4
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Scheipner Lukas
- Co-Autor*innen der Med Uni Graz
- Ahyai Sascha
- Hutterer Georg
- Pichler Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: To test for regional differences in clear cell metastatic renal cell carcinoma (ccmRCC) patients across the USA. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database (2000-2018) was used to tabulate patient (age at diagnosis, sex, race/ethnicity), tumor (N stage, sites of metastasis) and treatment characteristics (proportions of nephrectomy and systemic therapy), according to 12 SEER registries. Multinomial regression models, as well as multivariable Cox regression models, tested the overall mortality (OM) adjusting for those patient, tumor and treatment characteristics. RESULTS: In 9882 ccmRCC patients, registry-specific patient counts ranged from 4025 (41%) to 189 (2%). Differences across registries existed for sex (24-36% female), race/ethnicity (1-75% non-Caucasian), N stage (N1 25-35%, NX 3-13%), proportions of nephrectomy (44-63%) and systemic therapy (41-56%). Significant inter-registry differences remained after adjustment for proportions of nephrectomy (46-63%) and systemic therapy (35-56%). Unadjusted 5-year OM ranged from 73 to 85%. In multivariable analyses, three registries exhibited significantly higher OM (SEER registry 5: hazard ratio (HR) 1.20, p = 0.0001; SEER registry 7:HR 1.15, p = 0.008M SEER registry 10: HR 1.15, p = 0.04), relative to the largest reference registry (n = 4025). CONCLUSION: Important regional differences including patient, tumor and treatment characteristics exist, when ccmRCC patients included in the SEER database are studied. Even after adjustment for these characteristics, important OM differences persisted, which may require more detailed analyses to further investigate these unexpected differences.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Female - administration & dosage
- Male - administration & dosage
- Carcinoma, Renal Cell - epidemiology, surgery
- Kidney Neoplasms - pathology
- SEER Program - administration & dosage
- Proportional Hazards Models - administration & dosage
- Nephrectomy - methods
- Find related publications in this database (Keywords)
- SEER
- Metastatic RCC
- Regional
- Outcome
- Clear cell
- Population